Is BMRN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,107 people get BMRN articles and Market Currents by email alert.

Get email alerts on BMRN »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

BioMarin: Gains To Continue As Pipeline Progress Is Realized
PropThink • Mon, Mar 25
BioMarin's Expanding Product Portfolio Will Lead To Gains In 2013
PropThink • Mon, Dec 31, 2012
BioMarin Sees Major Rally On Phase III Orphan Drug
Brian L. Wilson • Tue, Nov 6, 2012 • 1 Comment
What's To Come At BioMarin
Chimera Research Group • Thu, Aug 2, 2012
How Much Further Can Rare Diseases Carry BioMarin?
Stephen Simpson • Thu, Mar 29, 2012
Biomarin - Fair Value of $50+: A Step-by-Step Analysis
Martin Shkreli • Wed, Jun 8, 2011 • 17 Comments
BioMarin Pipeline Update
Zacks Investment Research • Wed, Sep 1, 2010
BioMarin Rolls the Dice on a New Lupus Drug
Eben Tessari • Thu, Jan 8, 2009
Smallcap BioMarin's Drug Kuvan Showing Great Promise
Notable Calls • Tue, Feb 12, 2008
Look Who's Buying Shares of BioMarin Pharmaceutical
Lon Juricic • Tue, Jun 19, 2007
BioMarin Recieves Approval for Aldurazyme in Japan
H.S. Ayoub • Wed, Nov 1, 2006

To learn more about Seeking Alpha Pro, click here.

Cramer's Mad Money - Cheniere Energy CEO: 'Go Knock Yourself Out!' (6/3/13)
SA Editor Miriam Metzinger • Tue, Jun 4 • 1 Comment
Cramer's Mad Money - The Kids Love Tesla (5/20/13)
SA Editor Miriam Metzinger • Tue, May 21 • 1 Comment
Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pill
Michael_Anderson • Mon, May 20 • 3 Comments
1 Biotech, 1 Financial And 1 Grocery Store With Recent Intensive Insider Selling
Markus Aarnio • Thu, May 16 • 2 Comments
Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform
Tom Welch • Wed, May 1 • 2 Comments
Catalyst Deserves The Attention
Veziris Ventures • Tue, Apr 23 • 5 Comments
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013
Trade In Mexico • Thu, Apr 18 • 14 Comments
The 9 Levels Of Healthcare / Biotechnology And Who Should Invest - Part 1
Brian Nichols • Fri, Apr 5 • 4 Comments
Cramer's Mad Money - 12 Things To Watch In The Week Ahead (3/15/13)
SA Editor Miriam Metzinger • Sun, Mar 17 • 7 Comments
Cramer's Lightning Round - Stay Away From The Nuts At Diamond (3/12/13)
SA Editor Miriam Metzinger • Wed, Mar 13
Don't Fold On Amicus Therapeutics Just Yet
Stephen Simpson • Wed, Feb 27 • 13 Comments
Cramer's Lightning Round - Aqua America Is Starting To Roll (2/22/13)
SA Editor Miriam Metzinger • Mon, Feb 25 • 2 Comments
If Investors Won't Buy Shire, Big Pharma Should
Stephen Simpson • Wed, Feb 20
4 Biotech Stocks On The Clock
Stock Traders Daily • Tue, Feb 19
JPMorgan Healthcare Conference 2013: Ultra-Orphan Drug And Health IT Companies Lead The Way
Raymond Chung • Wed, Feb 6 • 4 Comments
5 Stocks With Recent Intensive Insider Selling
Markus Aarnio • Wed, Jan 30 • 7 Comments
Upcoming Orphan Drug Approval Decisions For 4 Biopharma Companies
LifeSci Advisors • Thu, Dec 20, 2012 • 2 Comments
Is Telik A Good Buy After Increasing 24% In One Day?
C.R. Jackson • Wed, Dec 12, 2012 • 1 Comment
7 High Growth Healthcare Stocks With Strong Inventory Trends
Kapitall • Wed, Dec 12, 2012
Hedge Funds Are Buying These 6 High-Growth Biotech Stocks
Kapitall • Thu, Nov 22, 2012 • 6 Comments

BioMarin Pharmaceutical Inc. Presents at UBS Global Healthcare Conference, May-21-2013 09:00 AM
Tue, May 21
BioMarin Pharmaceutical Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
BioMarin Pharmaceutical's CEO Hosts BMN-701 Phase I/II Trial Results Conference (Transcript)
Wed, Mar 20
BioMarin Pharmaceutical Management Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Feb 22
BioMarin Pharmaceutical Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Oct 25, 2012
BioMarin Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Fri, Apr 27, 2012
BioMarin Pharmaceutical's CEO Discusses Q4 2011 Earning Results - Earnings Call Transcript
Thu, Feb 16, 2012
BioMarin Pharmaceutical Presents at 30th Annual JP Morgan Healthcare Conference (Transcript)
Tue, Jan 10, 2012
BioMarin Pharmaceutical's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Thu, Oct 27, 2011
BioMarin Pharmaceutical's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Jul 29, 2011
BioMarin Pharmaceutical Inc. Q2 2009 Earnings Call Transcript
Thu, Jul 30, 2009
BioMarin Pharmaceutical Inc., Q1 2009 Earnings Call Transcript
Fri, May 1, 2009
BioMarin Pharmaceutical Inc. Q4 2008 Earnings Call Transcript
Wed, Feb 18, 2009
BioMarin Pharmaceutical Inc. Q3 2008 Earnings Conference Call Transcript
Tue, Oct 28, 2008
BioMarin Pharmaceutical, Inc. Q2 2008 Earnings Call Transcript
Wed, Aug 6, 2008
BioMarin Pharmaceutical, Inc. Q1 2008 Earnings Call Transcript
Wed, Apr 30, 2008
BioMarin Pharmaceutical, Inc. Q4 2007 Earnings Call Transcript
Tue, Mar 4, 2008

UPDATE: Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs Global Healthcare Conference

GlobeNewswire (Jun 6, 2013)
BioMarin to Present at the Goldman Sachs Global Healthcare Conference

GlobeNewswire (Jun 6, 2013)
BioMarin Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU

GlobeNewswire (Jun 5, 2013)
BioMarin Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting

GlobeNewswire (Jun 3, 2013)
What to Watch at This Year's Biotech Super Bowl

at CNBC.com (May 31, 2013)
BioMarin to Present at the Jefferies Global Healthcare Conference

GlobeNewswire (May 30, 2013)
FDA Accepts Vimizim BLA and Grants Priority Review Designation

GlobeNewswire (May 30, 2013)
Vimizim MAA Validated by the EMA

GlobeNewswire (May 30, 2013)
Cramer's Watch List Ahead of Big Cancer Conference

at CNBC.com (May 20, 2013)
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire (May 20, 2013)
BioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCO

GlobeNewswire (May 16, 2013)
BioMarin to Present at the UBS Global Healthcare Conference

GlobeNewswire (May 14, 2013)
BioMarin to Present at the Baird Growth Stock Conference

GlobeNewswire (May 2, 2013)
BioMarin Announces First Quarter 2013 Financial Results

GlobeNewswire (Apr 25, 2013)
BioMarin Submits Vimizim MAA to EMA for the Treatment of MPS IVA

GlobeNewswire (Apr 24, 2013)
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire (Apr 18, 2013)
BioMarin to Host First Quarter 2013 Financial Results Conference Call and Webcast on Thursday, April 25 at 5:00 p.m. ET

GlobeNewswire (Apr 4, 2013)
Cramer: Small Drug Stocks with Promising Pipelines

at CNBC.com (Apr 1, 2013)
BioMarin Submits CTA for BMN-190 for Batten Disease

GlobeNewswire (Apr 1, 2013)
BioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA

GlobeNewswire (Apr 1, 2013)

BMRN vs. ETF Alternatives

Company Description

Currently, there's no company description for BMRN.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, June 17, 3:14 PM Shares of ViroPharma (VPHM +7.2%) spike midday after rumors surface that the company could be an acquisition target. While "no deal is imminent," potential buyers have expressed "preliminary interest," according to three anonymous sources cited by Reuters. The company has declined to comment. BioMarin (BMRN -0.2%) is also mentioned although the company says it is "not actively looking to be acquired." Comment! [Healthcare, On the Move]
Wednesday, June 5, 11:28 AM BioMarin Pharmaceutical (BMRN -1.8%) initiates Phase 3 studies for PEG-PAL, or PEGylated recombinant Phenylalanine Ammonia Lyase, for the treatment of the genetic disorder phenylketonuria. In Phase 2 trials, the drug was shown to dramatically reduce blood Phe levels and the company is looking to achieve the same outcome in next phase. Comment! [Healthcare, On the Move]
Tuesday, June 4, 8:56 AM Deutsche Bank says the market is assigning exactly zero value to BioMarin's (BMRN) BMN 673, a faulty assumption in the mind of analyst Robyn Karnauskas, who upgrades the shares to Buy and maintains a $75 price target. There's room in the market for both Tesaro's (TSRO) Niraparib, and BMRN's PARP inhibitor as "the two drugs appear to have similar efficacy," although TSRO is ahead in development. Shares +1.44% premarket.(Previous: Leerink still likes BMN 673) Comment! [Healthcare]
Monday, June 3, 1:40 PM Leerink analyst Joseph Schwartz comes out in support of BioMarin (BMRN -7.5%) amid a sell-off in the shares. Results presented at ASCO (previous) were positive he says, noting that response rates for BMN 673 were "above the 30% threshold." Schwartz reiterates an Outperform rating and a $70 price target. Comment! [Healthcare, On the Move]
Monday, June 3, 11:20 AM Shares of BioMarin (BMRN -8.1%) sink in morning trading. Data presented at ASCO from an ongoing clinical trial of the PARP inhibitor BMN 673 showed RECIST rates of 44% and 39% for 28 gBRCA ovarian cancer patients and 18 gBRCA breast cancer patients respectively. In a note published Friday, Credit Suisse (Neutral, PT $68) assigned a risk adjustment of 50% to BMN 673 when modeling contributions from BMRN's pipeline. Comment! [Healthcare, On the Move]
Thursday, May 30, 12:45 PM BioMarin Pharmaceutical (BMRN -1.7%) says the FDA has granted priority-review designation to Vimizim, an enzyme-replacement therapy under evaluation for the treatment of the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA, also called Morquio A Syndrome. Comment! [Healthcare, On the Move]
Thursday, April 25, 4:10 PM Biomarin Pharmaceuticals (BMRN): Q1 EPS of -$0.31 misses by $0.01. Revenue of $127.9M (+9.7% Y/Y) misses by $3.54M. Shares -1.3% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Thursday, April 25, 12:10 AM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
Wednesday, April 24, 5:35 PM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
Wednesday, April 24, 4:22 PM BioMarin (BMRN) submits a Marketing Authorization Application to the European Medicines Agency for its enzyme replacement therapy Vimizim. Earlier this month, the company submitted a Biologics License Application to the FDA for the treatment after positive Phase III clinical results. Comment! [Healthcare]
Wednesday, March 20, 11:15 AM BioMarin Pharmaceutical (BMRN +0.7%) says results from Phase 1/2 trials for BMN-701, a treatment of late-onset Pompe disease, exceeded requirements for proceeding to the next phase of development. Pompe disease is a rare, inherited and often fatal disorder that disables the heart and skeletal muscles. The company plans to move on to Phase 2/3 trials for the treatment by the end of this year. Comment! [Healthcare, On the Move]
Thursday, February 21, 4:09 PM BioMarin Pharmaceuticals (BMRN): Q4 GAAP EPS of -$0.43. Revenue of $132M beats by $2.3M. Shares +0.9% AH. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, February 21, 12:10 AM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD Comment! [Earnings]
Wednesday, February 20, 5:35 PM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD 2 Comments [Earnings]
Tuesday, December 11, 2012, 2:02 PM Catalyst Pharmaceutical Partners (CPRX -2.4%) says it's issued 6,666,667 shares of its authorized but unissued common stock to BioMarin Pharmaceutical (BMRN +2.5%) upon the automatic conversion of a $5M loan that CPRX received from BMRN in October in connection with it's licensing of the North American rights to Firdapse. The shares were issued at a conversion price of $0.75 per share. Comment! [Healthcare, On the Move]
Thursday, November 15, 2012, 2:07 PM Shares or BioMarin Pharmaceutical (BMRN -0.7%) spiked over 10% in a faction of a second at the open this morning, hitting a new 52-week high of $52.96 before triggering a trading pause by Nasdaq. The five-minute halt was activated after scores of trades were executed at sharply higher prices in a burst of high volume at 9:50 a.m. EST., possibly resulting from a "fat finger" trade-input error. On a separate note, the company is currently presenting an update at the Credit Suisse Healthcare Conference in Phoenix, AZ. Comment! [Healthcare]

ltfinger
Returning Upgrades (5/3/13): $AMSG, $APOG, $ATU, $AVD, $AYI, $B, $BCO, $BMRN, $BPL, $BX, $CACI, $CBI, $CSOD, $CWT, $HEES, $HTSI, $INVN
May 6, 9:30 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Potential Downgrades (4/4/13): $AFL, $AIG, $ALKS, $ALV, $AMG, $AMZN, $ARMH, $ATHN, $ATLS, $AXP, $BAP, $BF.B, $BIDU, $BMC, $BMRN
Apr 5, 12:42 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Upgrades (3/28/13): $AIZ, $ALGT, $ALNY, $ALV, $ANSS, $APH, $ARII, $BDC, $BMRN, $BOFI, $BRK-B, $CAVM, $CBD, $CBS, $CELG, $CGNX
Apr 1, 9:09 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/kDzg Bearish call on $BMRN, 3k patient cannot generate 775 million in 2015. Its a sell with PT of 40. $PCYC" $BMRN
11/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/kDzs Pharmacyclics is not worth $51.30 with no FDA approved drug. Ideally its should be below 10. $PCYC $BMRN"
11/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/RNQTMf Bearish call on $BMRN, 3k patient cannot generate 775 million in 2015. Its a sell with PT of 40.
11/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/SNycwr Premarket Gainer and Loser for Nov 5th: $BMRN, $NTE, $EQU, $SF, $MAPP, $MEI, $MEG, $RDN
11/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Mid-Cap Stocks Holding Cash And Set For Growth http://bit.ly/T7lFkR $BMRN $KNM $MEOH $MLNX @ZetaKap
10/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jeff Pierce
$BMRN could be getting ready for the next leg up. http://bit.ly/OlwB0D
9/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
3 Mid Cap Stocks Loaded With Cash And Set To Grow http://bit.ly/PLDPXE $BMRN $CBST $KNM @ZetaKap
8/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

ZetaKap
$$ Just posted: 6 High-Growth Biotech Stocks Analysts Rate As Buys http://bit.ly/KZ6RCp $BONE $AFFY $ATHX $ALXN $ACOR $BMRN @ZetaKap
5/18/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Bacterin is definitely a Buy! Now if they could only do a better job of informing investors of how truly ground breaking their tech is.
Mar 8, 5:37 AM
• !Report Abuse
Add a reply...

140 characters

BMRN BioMarin Pharmaceutical Inc.

BMRN

BioMarin Pharmaceutical Inc.